|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 86.89 EUR | +1.95% |
|
+0.49% | -3.20% |
| Apr. 19 | Sector Update: Health Care Stocks Rise Friday Afternoon | MT |
| Apr. 19 | Global markets live: P&G, Amex, Blackstone, Apple, Tesla... |  |
PARIS (Reuters) - French healthcare company Sanofi, which has been under pressure to revive its drug pipeline after some setbacks in the COVID-19 vaccine race, announced on Friday a research deal with the company Exscientia to develop new medicines.
The two companies said they would work on developing an artificial-intelligence (AI) driven pipeline of new products in areas such as oncology and immunology.
Exscientia will also receive an upfront cash payment of $100 million with the potential of $5.2 billion in total milestones plus tiered royalties, as part of the deal with Sanofi.
(Reporting by Sudip Kar-Gupta; Editing by Kim Coghill)
| 1st Jan change | Capi. | |
|---|---|---|
| -3.20% | 113B | |
| +24.60% | 672B | |
| +24.08% | 550B | |
| -5.63% | 351B | |
| +15.37% | 317B | |
| +7.38% | 292B | |
| +3.26% | 211B | |
| +0.78% | 203B | |
| -9.69% | 144B | |
| -6.63% | 141B |
SANOFI 
